Alexandra C Sundermann1, Katherine E Hartmann2, Sarah H Jones1, Eric S Torstenson1, Digna R Velez Edwards3. 1. Vanderbilt Epidemiology Center, Institute of Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN. 2. Vanderbilt Epidemiology Center, Institute of Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN; Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN. 3. Vanderbilt Epidemiology Center, Institute of Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN; Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN. Electronic address: digna.r.velez.edwards@vanderbilt.edu.
Abstract
PURPOSE: Data about maternal recall accuracy for classifying early pregnancy medication exposure are meager. Nonetheless, studies often rely on recall to evaluate potential impact of pharmaceuticals on the developing fetus. METHODS: Right from the Start is a community-based pregnancy cohort that enrolled women from North Carolina, Tennessee, and Texas. A subset of 318 women participated in daily medication diaries initiated before conception (2006-2012). We examined nonsteroidal anti-inflammatory drugs (NSAIDs) as an example of a drug type that is difficult to study due to its intermittent and primarily over-the-counter use as well as its incomplete documentation in medical and pharmaceutical records. Selective serotonin reuptake inhibitors (SSRI) were assessed as a prescription medication comparator. Maternal recall of NSAID and SSRI use in early pregnancy was examined by comparing diary data (gold standard) to first-trimester interview. RESULTS: Sensitivity and specificity for recall of NSAID exposure were 78.6% and 62.3%, respectively (kappa statistic: 0.41), with 72.3% agreement for exposure classification. Sensitivity and specificity for recall of SSRI exposure were 77.8% and 99.0%, respectively (kappa statistic: 0.79), with 97.8% agreement. CONCLUSIONS: Our findings suggest the validity of maternal recall varies with medication type and prospective data collection should be prioritized when studying early pregnancy drug exposures.
PURPOSE: Data about maternal recall accuracy for classifying early pregnancy medication exposure are meager. Nonetheless, studies often rely on recall to evaluate potential impact of pharmaceuticals on the developing fetus. METHODS: Right from the Start is a community-based pregnancy cohort that enrolled women from North Carolina, Tennessee, and Texas. A subset of 318 women participated in daily medication diaries initiated before conception (2006-2012). We examined nonsteroidal anti-inflammatory drugs (NSAIDs) as an example of a drug type that is difficult to study due to its intermittent and primarily over-the-counter use as well as its incomplete documentation in medical and pharmaceutical records. Selective serotonin reuptake inhibitors (SSRI) were assessed as a prescription medication comparator. Maternal recall of NSAID and SSRI use in early pregnancy was examined by comparing diary data (gold standard) to first-trimester interview. RESULTS: Sensitivity and specificity for recall of NSAID exposure were 78.6% and 62.3%, respectively (kappa statistic: 0.41), with 72.3% agreement for exposure classification. Sensitivity and specificity for recall of SSRI exposure were 77.8% and 99.0%, respectively (kappa statistic: 0.79), with 97.8% agreement. CONCLUSIONS: Our findings suggest the validity of maternal recall varies with medication type and prospective data collection should be prioritized when studying early pregnancy drug exposures.
Authors: Audra L Gollenberg; Sunni L Mumford; Maureen A Cooney; Rajeshwari Sundaram; Germaine M Buck Louis Journal: J Reprod Med Date: 2011 Mar-Apr Impact factor: 0.142
Authors: Joanne H E Promislow; Christina M Makarushka; Jessica R Gorman; Penelope P Howards; David A Savitz; Katherine E Hartmann Journal: Paediatr Perinat Epidemiol Date: 2004-03 Impact factor: 3.980
Authors: Linda de Jonge; Hermien E K de Walle; Lolkje T W de Jong-van den Berg; Irene M van Langen; Marian K Bakker Journal: Drug Saf Date: 2015-08 Impact factor: 5.606
Authors: Allison A Eubanks; Carrie J Nobles; Micah J Hill; Alan H DeCherney; Keewan Kim; Lindsey A Sjaarda; Neil J Perkins; Aijun Ye; Jessica R Zolton; Robert M Silver; Enrique F Schisterman; Sunni L Mumford Journal: Reprod Toxicol Date: 2020-09-09 Impact factor: 3.143
Authors: Pingsheng Wu; Digna R Velez Edwards; Phillip Gorrindo; Alexandra C Sundermann; Eric S Torstenson; Sarah H Jones; Ronna L Chan; Katherine E Hartmann Journal: Pharmacotherapy Date: 2019-07-25 Impact factor: 4.705
Authors: Susan E Andrade; Anick Bérard; Hedvig M E Nordeng; Mollie E Wood; Marleen M H J van Gelder; Sengwee Toh Journal: Curr Epidemiol Rep Date: 2017-04-18
Authors: Pim van Montfort; Jessica Ppm Willemse; Carmen D Dirksen; Ivo Ma van Dooren; Linda Je Meertens; Marc Ea Spaanderman; Maartje Zelis; Iris M Zwaan; Hubertina Cj Scheepers; Luc Jm Smits Journal: JMIR Res Protoc Date: 2018-05-04